ArticleFrontiers in neurology2026
The temporal sequence of myasthenia gravis and neuromyelitis optica spectrum disorder: a case report and systematic review of 74 patients.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The co-occurrence of myasthenia gravis (MG) and neuromyelitis optica spectrum disorder (NMOSD) is rare, and their temporal sequence and shared pathogenesis remain poorly understood. Methods: We present the case of a 43-year-old woman with pre-existing acetylcholine receptor antibody (AChR-Ab) positive ocular MG who developed aquaporin-4 antibody (AQP4-Ab) positive NMOSD. Additionally, we conducted a systematic literature review up to July 2024 to identify similar cases. Results: Including the present case, 74 patients were analyzed. The cohort showed a marked female predominance (89.2%). MG onset significantly preceded NMOSD onset in most patients (93.2%), with a younger mean age at onset (28.19 vs. 41.02 years, Conclusion: This study suggests a consistent temporal pattern wherein MG predominantly precedes NMOSD, often by years, suggesting a possible shared autoimmune predisposition. The observed response to eculizumab highlights complement pathway inhibition as a potentially effective therapeutic strategy for this complex overlap syndrome, warranting further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.